Featured Research

from universities, journals, and other organizations

Quality of life significantly increases after uterine fibroid treatment, study finds

Date:
March 1, 2011
Source:
Radiological Society of North America
Summary:
Women who received one of three treatments for uterine fibroids said their symptoms diminished and their quality of life significantly increased, according to a new study.

Women who received one of three treatments for uterine fibroids at Brigham and Women's Hospital in Boston said their symptoms diminished and their quality of life significantly increased, according to a new study published in the May issue of Radiology.

Uterine fibroids are benign pelvic tumors that occur in as many as one in five women during their childbearing years. Although not all fibroids cause symptoms, some women experience heavy bleeding, pain and infertility. Treatment options include hysterectomy, minimally invasive uterine artery embolization (UAE) and a noninvasive MR-guided focused ultrasound (MRgFUS) procedure.

"When discussing treatment options for women with uterine fibroids, the pros and cons of each treatment option need to be outlined," said the study's lead author, Fiona M. Fennessy, M.D., Ph.D., assistant professor of radiology at Harvard Medical School. "But until now, we haven't been able to evaluate all of the options with health-related quality-of-life measures, assessing symptom relief as well as the pain, anxiety or recovery time associated with the treatment itself."

In the study, researchers surveyed a total of 197 women who underwent hysterectomy (62), UAE (74) and MRgFUS (61) for symptomatic uterine fibroids between 2004 and 2006. The mean ages of the women in three groups were 47, 44 and 47, respectively.

A utility weight (a single unit of measure that encompasses all the different quality-of-life benefits from a health care intervention) was obtained for each of the fibroid treatment options, allowing comparisons of quality of life before and after treatment.

In addition, short-term utility weights for the actual treatments the women underwent were compared, allowing comparison of the actual treatment experiences among the options. To do this, the researchers used the waiting trade-off (WTO) method, which is based on the fact that people tend to wait longer to avoid unpleasant tests or procedures. Analysis by the WTO method provides short-term quality-of-life tolls in terms of quality-adjusted life-weeks.

"Quality of life significantly increased following each of the fibroid treatment options," Dr. Fennessy said. "But patients rated the non- or minimally invasive treatments -UAE and MRgFUS -- more favorably."

Patients who underwent a hysterectomy reported that they would wait 21 weeks in order to avoid the procedure, while patients in the other two groups said they would put off their procedures by only 14 weeks.

The minimally invasive UAE procedure, which is increasingly used as an alternative to the surgical removal of the uterus (hysterectomy), requires only a small nick in the skin, through which a catheter is inserted to deliver particles that block blood flow to the fibroids. UAE may be associated with a number of days of pain and cramping. The MRgFUS procedure, which was approved by the U.S. Food and Drug Administration in 2004 as a treatment option for uterine fibroids, is noninvasive: it uses ultrasound energy to ablate the fibroids. MRgFUS is quick and painless for many, and symptom relief has been shown to occur by 12 weeks.

"In order to be widely adopted, MRgFUS must be deemed as beneficial as the established alternatives," Dr. Fennessy said. "Our study not only provides measures to aid in future cost-utility analysis of uterine fibroid treatments, but it may be helpful to patient and physician decision-making with regard to treatment options."


Story Source:

The above story is based on materials provided by Radiological Society of North America. Note: Materials may be edited for content and length.


Journal Reference:

  1. Fiona M. Fennessy, Chung Yin Kong, Clare M. Tempany, J. Shannon Swan. Quality-of-Life Assessment of Fibroid Treatment Options and Outcomes. Radiology, 2011; DOI: 10.1148/radiol.11100704

Cite This Page:

Radiological Society of North America. "Quality of life significantly increases after uterine fibroid treatment, study finds." ScienceDaily. ScienceDaily, 1 March 2011. <www.sciencedaily.com/releases/2011/03/110301091111.htm>.
Radiological Society of North America. (2011, March 1). Quality of life significantly increases after uterine fibroid treatment, study finds. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/03/110301091111.htm
Radiological Society of North America. "Quality of life significantly increases after uterine fibroid treatment, study finds." ScienceDaily. www.sciencedaily.com/releases/2011/03/110301091111.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins